Analysis of United States Drug Patent 8,895,064: Scope, Claims, and Landscape
United States Patent 8,895,064, granted on December 22, 2014, to Bristol-Myers Squibb Company, covers methods for treating Hepatitis C virus (HCV) infection. The patent's core claims focus on the administration of a specific combination therapy involving Daclatasvir, an NS5A inhibitor, and Asunaprevir, an NS3 protease inhibitor. This analysis details the patent's scope, key claims, and its position within the broader HCV treatment patent landscape.
What is the Core Technology Claimed in US Patent 8,895,064?
The central technology patented is a therapeutic regimen for treating chronic Hepatitis C virus infection. The method comprises administering Daclatasvir and Asunaprevir in specific dosing schedules and durations. The patent specifies treatment for patients infected with HCV genotype 1.
- Daclatasvir: A potent inhibitor of the HCV NS5A protein, essential for viral replication and assembly.
- Asunaprevir: An inhibitor of the HCV NS3 protease, which is required for the processing of viral polyproteins into mature functional proteins.
The patent defines a "treatment regimen" that includes:
- Administration of Daclatasvir at a dose of 60 mg once daily.
- Administration of Asunaprevir at a dose of 200 mg twice daily.
- A treatment duration of 24 weeks.
The claims further specify that the treatment is for a human subject infected with HCV genotype 1. The method is designed to achieve a sustained virologic response (SVR).
What are the Key Claims of US Patent 8,895,064?
US Patent 8,895,064 contains 10 claims, with the independent claims defining the core method of treatment.
Independent Claims:
-
Claim 1: A method for treating chronic Hepatitis C virus infection in a human subject infected with Hepatitis C virus genotype 1, comprising administering to the subject: Daclatasvir at a dose of 60 mg once daily; and Asunaprevir at a dose of 200 mg twice daily.
-
Claim 2: The method of claim 1, wherein the administering is for a period of 24 weeks.
Dependent Claims:
The dependent claims further refine the method by specifying additional parameters, such as the formulation of the drugs, the genotype of the HCV, and the desired outcome.
- Claim 3: The method of claim 1, wherein Daclatasvir is administered orally.
- Claim 4: The method of claim 1, wherein Asunaprevir is administered orally.
- Claim 5: The method of claim 1, wherein the subject is infected with Hepatitis C virus genotype 1a.
- Claim 6: The method of claim 1, wherein the subject is infected with Hepatitis C virus genotype 1b.
- Claim 7: The method of claim 1, wherein the Hepatitis C virus infection is chronic.
- Claim 8: The method of claim 1, wherein the administering results in a sustained virologic response.
- Claim 9: The method of claim 2, wherein the administering is for a period of 24 weeks.
- Claim 10: The method of claim 9, wherein the administering results in a sustained virologic response.
The claims are narrowly focused on the specific combination of Daclatasvir and Asunaprevir at defined dosages and durations for genotype 1 HCV. They do not broadly cover all NS5A or NS3 inhibitor combinations or treatments for other HCV genotypes.
What is the Scope of Protection Afforded by this Patent?
The scope of protection for US Patent 8,895,064 is limited to the specific method of treatment as defined in its claims. This means that any party wishing to practice this exact method of administering 60 mg of Daclatasvir once daily and 200 mg of Asunaprevir twice daily for 24 weeks to treat genotype 1 HCV infection would potentially infringe this patent.
The patent does not protect:
- The individual compounds Daclatasvir or Asunaprevir themselves. These compounds are likely covered by separate composition of matter patents.
- Combinations of Daclatasvir or Asunaprevir with other antiviral agents not explicitly claimed.
- Treatment regimens involving different dosages, frequencies, or durations of Daclatasvir and Asunaprevir.
- Treatment of HCV genotypes other than genotype 1.
- Preventative methods or diagnostic methods related to HCV.
The protection is centered on the method of use for a specific patient population and treatment protocol.
How Does this Patent Relate to Approved HCV Treatments?
US Patent 8,895,064 describes a treatment regimen that was a precursor to approved therapies for HCV. Daclatasvir (marketed as Daklinza) and Asunaprevir (marketed as Sunvepra) were developed and approved, often in combination, by Bristol-Myers Squibb.
The combination of Daclatasvir and Asunaprevir was approved by the U.S. Food and Drug Administration (FDA) in July 2015 for the treatment of chronic HCV genotype 1 infection in certain patient populations, specifically those who have not responded to previous treatment. This approval followed the patent's grant date. The approved regimen typically involved Daclatasvir 60 mg daily and Asunaprevir 200 mg twice daily for 24 weeks [1].
This patent would have provided market exclusivity for this specific treatment regimen during its effective patent life, preventing generic competition for this particular method of care. However, the landscape of HCV treatment has rapidly evolved with the introduction of pan-genotypic direct-acting antiviral (DAA) regimens that offer higher cure rates, shorter treatment durations, and broader applicability across all HCV genotypes.
What is the Patent Landscape for HCV Treatments Around 2014?
By 2014, the patent landscape for Hepatitis C virus treatments was becoming increasingly crowded and complex, driven by the rapid advancements in direct-acting antivirals (DAAs). This era marked a significant shift from interferon-based therapies to highly effective, well-tolerated DAA regimens.
Key trends in the HCV patent landscape around 2014 included:
- Composition of Matter Patents: Patents covering the molecular structures of novel antiviral compounds, such as NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors, were foundational. These patents provided broad protection for the drug molecules themselves.
- Method of Treatment Patents: Similar to US Patent 8,895,064, these patents claimed specific ways of using these compounds, including particular combinations, dosages, durations, and patient populations (e.g., specific genotypes, treatment-naïve vs. treatment-experienced).
- Formulation Patents: Patents protecting specific pharmaceutical formulations designed to enhance drug stability, bioavailability, or patient compliance.
- Combination Therapy Patents: As DAAs are highly effective in combination, numerous patents were filed and granted for synergistic combinations of different classes of antivirals. The patent in question is an example of such a method of treatment patent for a specific combination.
- Process Patents: Patents covering novel synthetic routes or manufacturing processes for producing the antiviral drugs.
- Geographic and Genotypic Specificity: Early DAA development often focused on specific HCV genotypes (e.g., genotype 1). Patents from this period frequently reflected this specificity, with claims tailored to particular genotypes. The rise of pan-genotypic regimens later shifted this focus.
- Evergreening Strategies: Pharmaceutical companies employed various strategies, including filing patents on new formulations, combinations, or methods of use, to extend market exclusivity beyond the expiry of initial composition of matter patents.
Major players in this landscape included Gilead Sciences (with sofosbuvir, ledipasvir, velpatasvir), AbbVie (with ombitasvir, paritaprevir, ritonavir, dasabuvir), Bristol-Myers Squibb (with daclatasvir, asunaprevir), and Merck. The intense patent activity reflected the high therapeutic need and significant commercial opportunity in treating HCV.
What is the Current Status of US Patent 8,895,064?
US Patent 8,895,064 was granted on December 22, 2014. Its term is typically 20 years from the filing date, subject to potential patent term extensions (PTE) in the United States if applicable. The filing date for this patent was December 27, 2011.
Therefore, the patent's original term would have expired around December 27, 2031. However, the actual expiry date depends on whether any PTE was granted and the specific rules governing patent terms in the US. Given the rapid evolution of HCV treatment, the practical impact of this method of treatment patent on current market dynamics may be limited, as more advanced and broadly effective therapies have emerged. The development and approval of pan-genotypic regimens have largely superseded the need for genotype-specific, multi-drug combinations like the one claimed here.
Key Takeaways
- US Patent 8,895,064 claims a specific method for treating chronic HCV genotype 1 infection using Daclatasvir (60 mg daily) and Asunaprevir (200 mg twice daily) for 24 weeks.
- The patent provides protection for this precise combination therapy regimen, not for the individual drug compounds or other variations.
- This patent describes a regimen that was approved by the FDA for certain HCV genotype 1 patients, reflecting its clinical relevance at the time of approval.
- The patent landscape for HCV treatments in 2014 was characterized by extensive patenting of novel DAA compounds, combinations, and methods of use.
- The original term of the patent is expected to expire around December 27, 2031, though actual expiry depends on extensions.
FAQs
-
Does US Patent 8,895,064 cover the individual drugs Daclatasvir and Asunaprevir?
No, the patent covers a specific method of treatment using these drugs in combination, not the drugs themselves. Separate patents would cover the composition of matter for each compound.
-
Can I use Daclatasvir and Asunaprevir together to treat other HCV genotypes under this patent?
No, the claims of US Patent 8,895,064 are explicitly limited to treating Hepatitis C virus genotype 1.
-
What is the significance of the 24-week treatment duration mentioned in the patent?
The 24-week duration is a specific parameter claimed as part of the method of treatment. Practicing the treatment with a significantly different duration could fall outside the scope of this patent's claims.
-
Has this patent expired?
The original term of US Patent 8,895,064 is expected to expire around December 27, 2031, subject to any patent term extensions.
-
Are there newer HCV treatments that are not covered by this patent?
Yes, numerous newer HCV treatments, particularly pan-genotypic direct-acting antiviral regimens with different drug compositions and shorter treatment durations, are not covered by the specific claims of US Patent 8,895,064.
Citations
[1] U.S. Food & Drug Administration. (2015, July 24). FDA approves Daklinza and Sunvepra combination for treatment of chronic Hepatitis C genotype 1 infection. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daklinza-and-sunvepra-combination-treatment-chronic-hepatitis-c-genotype-1-infection
